LeMaitre Vascular, Inc.

LeMaitre's 35.2x P/E multiple is striking for a $2.2B medical-device maker, especially against an RSI of 32.4 that signals oversold conditions. The stock trades below its 52-week high while carrying modest short interest at 6.35% of float—suggesting institutional conviction hasn't wavered despite recent weakness. The valuation premium reflects likely confidence in its vascular-access franchise, but the divergence between elevated multiples and depressed momentum creates tension. Either the market is pricing in significant earnings acceleration ahead, or there's risk of multiple compression if growth disappoints. The setup presents neither obvious panic-selling nor euphoric momentum; it's more a patience test for quality-at-a-price believers.